|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 96.92 USD | -0.92% |
|
+1.43% | -1.87% |
| 17/04 | Goldman Sachs Adjusts Incyte Price Target to $100 From $98, Maintains Neutral Rating | MT |
| 14/04 | Pharma sector doubles down on AI amid hopes of slashing costs, timelines | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5d. change | Varia. Jan 1. | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| INCYTE CORPORATION | Biopharmaceuticals | -0.92% | +1.43% | -1.87% | +66.50% | +14.60% | 1.95TCr |  |  | |
- Stock Market
- Equities
- INCY Stock
- Charts Incyte Corporation
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition